Trump's 200% drug tariff plan: Is India's pharma industry about to face an economic storm?

The United States is set to implement a phased approach to tariffs on generic drug imports, beginning at zero percent and escalating to one hundred percent, eventually reaching two hundred percent by 2028. This strategy is designed to foster the onshoring of pharmaceutical manufacturing. India, a significant supplier, could experience considerable repercussions, though it will benefit from a grace period of two years.